Companies › Revolution Medicines
8 active drug programs in 49 registered trials: 22 Phase 1, 19 Phase 2, 8 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RMC-6236 RAS(ON) inhibitor - KRAS G12C inhibitor | KRAS | Phase 3 | Pancreatic Cancer; Non-small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer, NSCLC; Colorectal Cancer | Dec 2026 |
| Daraxonrasib KRAS(ON) inhibitor | KRAS | Phase 3 | NSCLC (Non-small Cell Lung Cancer); Pancreatic Cancer; Non-small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer (NSCLC) … | Dec 2027 |
| Zoldonrasib KRAS(ON) inhibitor | KRAS | Phase 3 | Pancreatic Cancer; NSCLC; Advanced Solid Tumors | Dec 2028 |
| RMC-9805 RAS(ON) inhibitor - KRAS inhibitor | KRAS | Phase 1 | Non-small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer, NSCLC; Colorectal Cancer | Dec 2026 |
| RMC-6291 KRAS(ON) inhibitor | KRAS | Phase 1 | Non-Small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer, NSCLC | Mar 2027 |
| RMC-5127 KRAS G12V inhibitor | – | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Apr 2028 |
| Elironrasib KRAS(ON) inhibitor | KRAS | Phase 1 | Non-Small Cell Lung Cancer (NSCLC); Advanced Solid Tumors | Dec 2028 |
| Ivonescimab PD-1 and CTLA-4 dual antagonist | PD-1, CTLA4 | Phase 1 | Advanced Solid Tumors; Stomach Cancer Stage IV; Small Cell Lung Cancer; Recurrent or Metastatic Nasopharyngeal Carcinoma … | May 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07070466 | Ivonescimab | Phase 2 | Stomach Cancer Stage IV | Oncology | Dec 2026 |
| NCT06769971 | Ivonescimab | Phase 2 | Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06040541 | RMC-6236 | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Oncology | Dec 2026 |
| NCT06040541 | RMC-9805 | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Oncology | Dec 2026 |
| NCT07070479 | Ivonescimab | Phase 2 | Recurrent or Metastatic Nasopharyngeal Carcinoma | Oncology | Jan 2027 |
| NCT07162714 | Ivonescimab | Phase 2 | Rectal Cancer | Oncology | Mar 2027 |
| NCT05462717 | RMC-6291 | Phase 1 | Non-Small Cell Lung Cancer (NSCLC) | Oncology | Mar 2027 |
| NCT06925724 | Ivonescimab | Phase 2 | Endometrial Cancer | Oncology | Apr 2027 |
| NCT07655570 | Ivonescimab | Phase 2 | Cutaneous Angiosarcoma | Oncology | May 2027 |
| NCT05379985 | RMC-6236 | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Oncology | May 2027 |
| NCT06162221 | RMC-6236 | Phase 1 | Non-Small Cell Lung Cancer, NSCLC | Oncology | Jun 2027 |
| NCT06162221 | RMC-9805 | Phase 1 | Non-Small Cell Lung Cancer, NSCLC | Oncology | Jun 2027 |
| NCT06162221 | RMC-6291 | Phase 1 | Non-Small Cell Lung Cancer, NSCLC | Oncology | Jun 2027 |
| NCT06491472 | Ivonescimab | Phase 2 | Pancreatic Cancer | Oncology | Jul 2027 |
| NCT06529718 | Ivonescimab | Phase 2 | Biliary Tract Cancer | Oncology | Aug 2027 |
| NCT07229417 | Ivonescimab | Phase 2 | Metastatic Endocrine Refractory | Oncology | Sep 2027 |
| NCT06881784 | Daraxonrasib | Phase 3 | NSCLC (Non-small Cell Lung Cancer) | Oncology | Dec 2027 |
| NCT07017673 | Ivonescimab | Phase 2 | TNBC | Oncology | Dec 2027 |
| NCT06625320 | RMC-6236 | Phase 3 | Pancreatic Cancer | Oncology | Dec 2027 |
| NCT07472478 | Ivonescimab | Phase 2 | Lung Cancer (NSCLC) | Oncology | Dec 2027 |
| NCT06875076 | Ivonescimab | Phase 2 | Pretreated Pleural Mesothelioma | Oncology | Jan 2028 |
| NCT06940518 | Ivonescimab | Phase 2 | Ivonescimab | Oncology | Jan 2028 |
| NCT06672575 | Ivonescimab | Phase 1 | Glioblastoma | Oncology | Jan 2028 |
| NCT06840834 | Ivonescimab | Phase 2 | Pleural Mesotheliomas | Oncology | Mar 2028 |
| NCT07349537 | Daraxonrasib | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Oncology | Apr 2028 |
| NCT07535463 | Ivonescimab | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Apr 2028 |
| NCT07535437 | Ivonescimab | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Apr 2028 |
| NCT07349537 | RMC-5127 | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Oncology | Apr 2028 |
| NCT07594522 | Ivonescimab | Phase 1 | Non-Small Cell Lung Cancer | Oncology | May 2028 |
| NCT07076693 | Ivonescimab | Phase 2 | OligoProgressive Metastatic Disease | Oncology | May 2028 |
| NCT07491445 | Daraxonrasib | Phase 3 | Pancreatic Cancer | Oncology | Jun 2028 |
| NCT06959550 | Ivonescimab | Phase 2 | Metastatic Colorectal Cancer | Oncology | Jul 2028 |
| NCT06951646 | Ivonescimab | Phase 2 | Non Small Cell Lung Cancer | Oncology | Jul 2028 |
| NCT06567314 | Ivonescimab | Phase 2 | Cutaneous Squamous Cell Carcinoma | Oncology | Sep 2028 |
| NCT06445062 | RMC-6236 | Phase 1 | Colorectal Cancer | Oncology | Sep 2028 |
| NCT06445062 | RMC-9805 | Phase 1 | Colorectal Cancer | Oncology | Sep 2028 |
| NCT06128551 | Daraxonrasib | Phase 1 | Non-Small Cell Lung Cancer (NSCLC) | Oncology | Dec 2028 |
| NCT06128551 | Elironrasib | Phase 1 | Non-Small Cell Lung Cancer (NSCLC) | Oncology | Dec 2028 |
| NCT07621718 | Zoldonrasib | Phase 3 | Pancreatic Cancer | Oncology | Dec 2028 |
| NCT07805954 | Daraxonrasib | Phase 3 | Pancreatic Cancer | Oncology | Mar 2029 |
| NCT07805954 | Zoldonrasib | Phase 3 | Pancreatic Cancer | Oncology | Mar 2029 |
| NCT07516925 | Ivonescimab | Phase 2 | Leiomyosarcoma | Oncology | Apr 2029 |
| NCT07252232 | Daraxonrasib | Phase 3 | Pancreatic Cancer | Oncology | May 2029 |
| NCT07397338 | Daraxonrasib | Phase 1 | Advanced Solid Tumors | Oncology | May 2029 |
| NCT07397338 | Elironrasib | Phase 1 | Advanced Solid Tumors | Oncology | May 2029 |
| NCT07397338 | Zoldonrasib | Phase 1 | Advanced Solid Tumors | Oncology | May 2029 |
| NCT07397338 | Ivonescimab | Phase 1 | Advanced Solid Tumors | Oncology | May 2029 |
| NCT07619339 | Ivonescimab | Phase 1 | Non-Small Cell Lung Cancer | Oncology | May 2029 |
| NCT07777822 | Zoldonrasib | Phase 3 | NSCLC | Oncology | Oct 2029 |
Cash and short-term investments of $3.7bn on 2026-09-30; operating cash outflow about $1.6bn a year; runway about 28 months at that burn, to Feb 2029; 6 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 19 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
BicycleTx Erasca IDEAYA Biosciences Kumquat Biosciences Vividion Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.